JAMES C YAO to Neoplasms
This is a "connection" page, showing publications JAMES C YAO has written about Neoplasms.
Connection Strength
0.484
-
Financial Outcomes of "Bagging" Oncology Drugs Among Privately Insured Patients With Cancer. JAMA Netw Open. 2023 09 05; 6(9):e2332643.
Score: 0.141
-
Accelerated approval and breakthrough therapy designation: oncology drug development on speed? Clin Cancer Res. 2013 Aug 15; 19(16):4305-8.
Score: 0.070
-
Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev. 2008 Apr; 17(4):959-65.
Score: 0.048
-
EPA, DHA, and resolvin effects on cancer risk: The underexplored mechanisms. Prostaglandins Other Lipid Mediat. 2024 Oct; 174:106854.
Score: 0.037
-
Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market. JNCI Cancer Spectr. 2021 08; 5(4).
Score: 0.030
-
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080.
Score: 0.028
-
Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. JAMA Oncol. 2019 03 01; 5(3):402-405.
Score: 0.026
-
Underreporting of Research Biopsies from Clinical Trials in Oncology. Clin Cancer Res. 2017 Nov 01; 23(21):6450-6457.
Score: 0.023
-
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
Score: 0.023
-
Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res. 2017 Mar 15; 23(6):1414-1421.
Score: 0.022
-
From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol. 2015 Nov 01; 33(31):3583-90.
Score: 0.020
-
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol. 2013 Jan 01; 31(1):17-22.
Score: 0.017